Edwards Lifesciences Sees FY24 Adj. EPS $2.70-$2.80 Vs $2.76 Est; Revenue $6.6B Vs $6.481B Est.
Portfolio Pulse from Benzinga Newsdesk
Edwards Lifesciences projects its FY24 adjusted EPS to be between $2.70 and $2.80, surpassing the estimated $2.76. The company also forecasts revenue of $6.6 billion, exceeding the expected $6.481 billion.
February 06, 2024 | 9:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Edwards Lifesciences projects higher-than-expected FY24 adjusted EPS and revenue, indicating strong future financial performance.
Edwards Lifesciences' projection of both higher adjusted EPS and revenue for FY24 than analysts' estimates suggests confidence in the company's growth and operational efficiency. This positive outlook is likely to instill investor confidence, potentially leading to a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100